What is the price of Psyence Biomedical Ltd. (PBM)

The price of Psyence Biomedical Ltd. (PBM) is $3.20

What is the market cap of Psyence Biomedical Ltd. (PBM)

The market cap of Psyence Biomedical Ltd. (PBM) is $60.86K

Psyence Biomedical Ltd. (PBM) Price and Market Cap

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Price of PBM	Asset B	Mkt. of B	Results
$287,407,072 $60.86K	NVDA	$5.466T	+8,981,470,900.38%
$235,496,567 $60.86K	AAPL	$4.479T	+7,359,267,626.02%
$219,555,251 $60.86K	GOOG	$4.176T	+6,861,101,488.68%
$193,995,861 $60.86K	MSFT	$3.690T	+6,062,370,562.23%
$151,540,554 $60.86K	AMZN	$2.882T	+4,735,642,223.14%

Price of PBM

Asset B

Mkt. of B

Results

$287,407,072 $60.86K